COVID-19 in pregnant women

References

1. 1.↵
   1. Huang C,
   2. Wang Y,
   3. Li X,
   4. Ren L,
   5. Zhao J,
   6. Hu Y, et al.

   Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Oğlak SC,
   2. Obut M.

   The risk of vicarious trauma among front-line and non-front-line midwives and nurses: Vicarious traumatization among medical staff. Aegean J Obstet Gynecol 2020; 2: 1–4.

   OpenUrl
3. 3.↵
   World Health Organization. Timeline COVID-19. (Updated 2022; Accessed 2020 May 15]. Available form: https://www.who.int/news-room/detail/27-04-2020-who-timeline—covid-19
4. 4.↵
   1. Can E,
   2. Oğlak SC,
   3. Ölmez F.

   Abnormal liver function tests in pregnant patients with COVID-19 - a retrospective cohort study in a tertiary center. Ginekol Pol 2022; 93; 151–157.

   OpenUrl
5. 5.↵
   1. Baj J,
   2. Karakuła-Juchnowicz H,
   3. Teresiński G,
   4. Buszewicz G,
   5. Ciesielka M,
   6. Sitarz E, et al.

   COVID-19: Specific and non-specific clinical manifestations and symptoms: The current state of knowledge. J Clin Med 2020; 9: 1753.

   OpenUrl
6. 6.↵
   1. Moore KM,
   2. Suthar MS.

   Comprehensive analysis of COVID-19 during pregnancy. Biochem Biophys Res Commun 2021; 538: 180–186.

   OpenUrl
7. 7.↵
   1. Harrison AG,
   2. Lin T,
   3. Wang P.

   Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol 2020; 41:1100–1115.

   OpenUrlPubMed
8. 8.↵
   1. Gupta A,
   2. Madhavan MV,
   3. Sehgal K,
   4. Nair N,
   5. Mahajan S,
   6. Sehrawat TS, et al.

   Extrapulmonary manifestations of COVID-19. Nat Med 2020; 26: 1017–1032.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Silasi M,
   2. Cardenas I,
   3. Kwon JY,
   4. Racicot K,
   5. Aldo P,
   6. Mor G.

   Viral infections during pregnancy. Am J Reprod Immunol 2015; 73: 199–213.

   OpenUrlCrossRefPubMed
10. 10.
    1. Oğlak SC,
    2. Obut M.

    Expression of ADAMTS13 and PCNA in the placentas of gestational diabetic mothers. Int J Morphol 2021; 39: 38–44.

    OpenUrl
11. 11.
    1. Behram M,
    2. Oğlak SC,
    3. Doğan Y.

    Evaluation of BRD4 levels in patients with early-onset preeclampsia. J Gynecol Obstet Hum Reprod 2021; 50: 101963.

    OpenUrl
12. 12.
    1. Behram M,
    2. Oğlak SC,
    3. Dağ İ.

    Circulating levels of Elabela in pregnant women complicated with intrauterine growth restriction. J Gynecol Obstet Hum Reprod 2021; 50: 102127.

    OpenUrl
13. 13.
    1. Behram M,
    2. Oğlak SC.

    The expression of angiogenic protein Cyr61 significantly increases in the urine of early-onset preeclampsia patients. J Contemp Med 2021; 11: 605–609.

    OpenUrlCrossRef
14. 14.↵
    1. Oğlak SC,
    2. Tunç Ş,
    3. Ölmez F.

    First trimester mean platelet volume, neutrophil to lymphocyte ratio, and platelet to lymphocyte ratio values are useful markers for predicting preeclampsia. Ochsner J 2021; 21: 364–370.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. LoMauro A,
    2. Aliverti A.

    Respiratory physiology of pregnancy: Physiology masterclass. Breathe (Sheff) 2015; 11: 297–301.

    OpenUrl
16. 16.↵
    1. Vale AJM,
    2. Fernandes ACL,
    3. Guzen FP,
    4. Pinheiro FI,
    5. de Azevedo EP,
    6. Cobucci RN.

    Susceptibility to COVID-19 in pregnancy, labor, and postpartum period: Immune system, vertical transmission, and breastfeeding. Front Glob Womens Health 2021; 2: 602572.

    OpenUrl
17. 17.↵
    1. Carsana L,
    2. Sonzogni A,
    3. Nasr A,
    4. Rossi RS,
    5. Pellegrinelli A,
    6. Zerbi P, et al.

    Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020; 20: 1135–1140.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Ackermann M,
    2. Verleden SE,
    3. Kuehnel M,
    4. Haverich A,
    5. Welte T,
    6. Laenger F, et al.

    Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383: 120–128.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Brosnihan KB,
    2. Neves LA,
    3. Anton L,
    4. Joyner J,
    5. Valdes G,
    6. Merrill DC.

    Enhanced expression of Ang-(1-7) during pregnancy. Braz J Med Biol Res 2004; 37: 1255–1262.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Zambrano LD,
    2. Ellington S,
    3. Strid P,
    4. Galang RR,
    5. Oduyebo T,
    6. Tong VT, et al.

    Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 1641–1647.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. T.C. Sağlık Bakanlığı

    COVID-19 Bilgilendirme Platformu.Republic of Turkey Ministry of Health. COVID-19 Information Platform [Updated 2022; Accessed 2020 June 4]. Available from: https://covid19.saglik.gov.tr/Eklenti/41940/0/covid19-toplumdasalginyonetimirehberi-19112021pdf.pdf
22. 22.↵
    1. Ellington S,
    2. Strid P,
    3. Tong VT,
    4. Woodworth K,
    5. Galang RR,
    6. Zambrano LD, et al.

    Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 769–775.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Mohr-Sasson A,
    2. Chayo J,
    3. Bart Y,
    4. Meyer R,
    5. Sivan E,
    6. Mazaki-Tovi S, et al.

    Laboratory characteristics of pregnant compared to non-pregnant women infected with SARS-CoV-2. Arch Gynecol Obstet 2020; 302: 1–6.

    OpenUrl
24. 24.↵
    1. Diriba K,
    2. Awulachew E,
    3. Getu E.

    The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal transmission: a systematic review and meta-analysis. Eur J Med Res 2020; 25: 39.

    OpenUrlCrossRefPubMed